Working… Menu
Trial record 1 of 1 for:    FASCINATION | Leipzig, Germany
Previous Study | Return to List | Next Study

Frontline Asciminib Combination in Chronic Phase CML (CMLXI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03906292
Recruitment Status : Recruiting
First Posted : April 8, 2019
Last Update Posted : January 29, 2021
Ludwig-Maximilians - University of Munich
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Thomas Ernst, PD Dr. med., University of Jena

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : November 2022
Estimated Study Completion Date : November 2022